352 related articles for article (PubMed ID: 25961456)
1. Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.
Abravanel DL; Belka GK; Pan TC; Pant DK; Collins MA; Sterner CJ; Chodosh LA
J Clin Invest; 2015 Jun; 125(6):2484-96. PubMed ID: 25961456
[TBL] [Abstract][Full Text] [Related]
2. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
4. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors.
Hirose H; Ishii H; Mimori K; Ohta D; Ohkuma M; Tsujii H; Saito T; Sekimoto M; Doki Y; Mori M
Oncol Rep; 2010 Jan; 23(1):35-43. PubMed ID: 19956862
[TBL] [Abstract][Full Text] [Related]
5. The transcriptional repressor Snail promotes mammary tumor recurrence.
Moody SE; Perez D; Pan TC; Sarkisian CJ; Portocarrero CP; Sterner CJ; Notorfrancesco KL; Cardiff RD; Chodosh LA
Cancer Cell; 2005 Sep; 8(3):197-209. PubMed ID: 16169465
[TBL] [Abstract][Full Text] [Related]
6. Ceramide kinase promotes tumor cell survival and mammary tumor recurrence.
Payne AW; Pant DK; Pan TC; Chodosh LA
Cancer Res; 2014 Nov; 74(21):6352-63. PubMed ID: 25164007
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies: Notching up dormant tumour-cell deaths to avoid recurrence.
Hutchinson L
Nat Rev Clin Oncol; 2015 Aug; 12(8):437. PubMed ID: 26011487
[No Abstract] [Full Text] [Related]
9. SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling.
Feng Y; Pan TC; Pant DK; Chakrabarti KR; Alvarez JV; Ruth JR; Chodosh LA
Cancer Discov; 2014 Jul; 4(7):790-803. PubMed ID: 24786206
[TBL] [Abstract][Full Text] [Related]
10. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
12. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer.
Holdman XB; Welte T; Rajapakshe K; Pond A; Coarfa C; Mo Q; Huang S; Hilsenbeck SG; Edwards DP; Zhang X; Rosen JM
Breast Cancer Res; 2015 Nov; 17():141. PubMed ID: 26581390
[TBL] [Abstract][Full Text] [Related]
15. Special AT-rich sequence-binding protein-1 participates in the maintenance of breast cancer stem cells through regulation of the Notch signaling pathway and expression of Snail1 and Twist1.
Sun Z; Zhang C; Zou X; Jiang G; Xu Z; Li W; Xie H
Mol Med Rep; 2015 May; 11(5):3235-542. PubMed ID: 25586771
[TBL] [Abstract][Full Text] [Related]
16. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.
Pradeep CR; Köstler WJ; Lauriola M; Granit RZ; Zhang F; Jacob-Hirsch J; Rechavi G; Nair HB; Hennessy BT; Gonzalez-Angulo AM; Tekmal RR; Ben-Porath I; Mills GB; Domany E; Yarden Y
Oncogene; 2012 Feb; 31(7):907-17. PubMed ID: 21743488
[TBL] [Abstract][Full Text] [Related]
17. Optical Imaging of Glucose Uptake and Mitochondrial Membrane Potential to Characterize Her2 Breast Tumor Metabolic Phenotypes.
Madonna MC; Fox DB; Crouch BT; Lee J; Zhu C; Martinez AF; Alvarez JV; Ramanujam N
Mol Cancer Res; 2019 Jul; 17(7):1545-1555. PubMed ID: 30902832
[TBL] [Abstract][Full Text] [Related]
18. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.
Pérez-Gómez E; Andradas C; Blasco-Benito S; Caffarel MM; García-Taboada E; Villa-Morales M; Moreno E; Hamann S; Martín-Villar E; Flores JM; Wenners A; Alkatout I; Klapper W; Röcken C; Bronsert P; Stickeler E; Staebler A; Bauer M; Arnold N; Soriano J; Pérez-Martínez M; Megías D; Moreno-Bueno G; Ortega-Gutiérrez S; Artola M; Vázquez-Villa H; Quintanilla M; Fernández-Piqueras J; Canela EI; McCormick PJ; Guzmán M; Sánchez C
J Natl Cancer Inst; 2015 Jun; 107(6):djv077. PubMed ID: 25855725
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.
Grudzien P; Lo S; Albain KS; Robinson P; Rajan P; Strack PR; Golde TE; Miele L; Foreman KE
Anticancer Res; 2010 Oct; 30(10):3853-67. PubMed ID: 21036696
[TBL] [Abstract][Full Text] [Related]
20. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L; Ghedini GC; Koschorke A; Triulzi T; Dugo M; Gasparini P; Casalini P; Palladini A; Iezzi M; Lamolinara A; Lollini PL; Nanni P; Chiodoni C; Tagliabue E; Pupa SM
Oncogene; 2017 Mar; 36(12):1721-1732. PubMed ID: 27641338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
